GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

GO-203

Solid Tumor Phase 1 Clinical Trial: GO-203

Rationale

GO-203 is a stable, rationally designed D-amino acid peptide that targets the MUC1-C cytoplasmic domain at the CQC motif, which is necessary and sufficient for the formation of MUC1-C homodimers and thereby its oncogenic function. GO-203 is active against MUC1-expressing human cancer cells growing in vitro and as tumor xenografts in mice.

Preclinical toxicology studies

Safety assessment of GO-203 was performed in rat and dog, which share homology with the human MUC1-C cytoplasmic domain. The results of the PK and safety assessment evaluations demonstrated an excellent safety profile for GO-203 and supported the first-in-human Phase 1 clinical trial.

Phase 1 human clinical study

Study GO-2C-001 was a Phase 1, multi-center, open-label, dose-escalation study evaluating the safety, PD, and PK of GO-203 in patients with advanced solid tumors or lymphomas. The primary objectives were to define DLTs and establish the MTD. Twenty-three patients were enrolled with 21 patients receiving at least one dose of GO-203, and 15 patients completing the study. GO-203 doses of 1.6, 3.2, 6.5, 12.5, 19.0, 25.5, and 38.0 mg/m2 were administered intravenously each day for 21 days. A highly acceptable toxicity profile was seen with CTCAE Grade 1-3 AEs reported in 20/21 treated patients. Most of the AEs were of CTCAE Grade 1 or 2 severity, and the majority were unlikely related or not related to GO-203 treatment. An asymptomatic, reversible increase in liver enzymes was observed at the higher doses. The dose of 25.5 mg/m2/day was defined as the MTD. The PK of GO-203 was dose-proportional with a terminal half-life of 5 to 16 hours.

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2021 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target